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BACKGROUND: Our aim was to evaluate whether extending the interval between human chorionic gonadotrophin
(hCG) priming and immature oocyte retrieval increases the oocyte maturation rate following in vitro maturation
(IVM). METHODS: This study was performed retrospectively. IVM was performed on 113 polycystic ovary syn-
drome patients (n 5 120 cycles). Oocyte collection was performed either 35 h (Group 1; n 5 76) or 38 h (Group 2;
n 5 44) after 10 000 IU of hCG priming. Following oocyte retrieval, oocyte maturity was assessed and the remaining
immature oocytes were cultured in IVM medium up to Day 2. RESULTS: The number of in vivo matured oocytes
collected was signiﬁcantly higher in Group 2 (13.6%, 114/840 versus 7.3%, 96/1312 in Group 1) (P<0.01); the
oocyte maturation rate after Day 1 was signiﬁcantly higher (P<0.01) in Group 2 (46.3 versus 36.0% in Group 1);
and clinical pregnancy (40.9 versus 25%) and implantation rates (15.6 versus 9.6%) were better in Group 2 than
those in Group 1. CONCLUSIONS: The results suggest that extending the period of hCG priming time from 35 to
38 h for immature oocyte retrieval promotes oocyte maturation in vivo and increases the IVM rate of immature
oocytes. Therefore, oocyte retrieval after 38 h of hCG priming may improve subsequent pregnancy outcome in
cycles programmed for IVM treatment.
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Introduction
There is an increasing interest in in vitro maturation (IVM) as
well as natural-cycle in in vitro fertilization (IVF) and minimal
stimulation regimes in the past few years. Although numerous
studies on IVM of immature human oocytes have been per-
formed, compared with the controlled ovarian hyperstimula-
tion (COH) cycles, the efﬁciency of current IVM techniques
is still suboptimal in terms of the number of mature oocytes
obtained, embryo developmental competence and implantation
rates. Therefore, several attempts have been made to improve
the viability of IVM oocytes by gonadotrophin stimulation
prior to oocyte collection (Wynn et al., 1998; Chian et al.,
2000). Chian et al. (1999, 2000) reported good pregnancy
rates by hCG priming (10 000 IU) before immature oocyte
retrieval from women with polycystic ovary syndrome
(PCOS) and this has been conﬁrmed by some other groups
(Lin et al., 2003; Son et al., 2007).
There are several embryological studies evaluating the
advantages of using hCG priming in IVM cycles (Yang
et al., 2005; Son et al., 2006, 2007). First, it has been reported
that immature oocytes with dispersed cumulus cells (CCs) only
appeared at the time of oocyte retrieval in the hCG-primed
IVM cycles and that immature oocytes with dispersed CC
showed better IVM and higher embryo developmental poten-
tial than those with compacted or sparse CC (Yang et al.,
2005; Son et al., 2006). Secondly, a few in vivo matured
oocytes with dispersed CC at the time of collection can be
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Advance Access publication on June 12, 2008obtained even in IVM cycles (Son et al., 2002, 2005, 2006),
and these have produced better quality embryos than those
derived from in vitro matured oocytes, resulting in better
clinical pregnancy rates (Son et al., 2008). Based on the
above embryological observations, it is very important to ﬁnd
ways to increase the number of oocytes with dispersed CC at
the time of retrieval in order to improve in vivo/IVM rates,
embryo developmental competence and clinical outcome.
It has been reported that a prolonged interval between hCG
administration and oocyte retrieval in conventional COH
cycles increased the production of oocytes with fully expanded
CC, follicular maturation and embryo developmental compe-
tence (Gudmundsson et al.,1990; Bokal et al., 2005; Raziel
et al., 2006). In IVM cycles, however, the effects on the embry-
ological aspects and clinical outcome of oocytes obtained fol-
lowing a prolonged interval of 38 h between hCG priming and
oocyte retrieval in PCOS patients have not been evaluated.
Therefore, this study was conducted to evaluate whether
extending the interval between hCG priming (from 35 to
38 h) and the time of oocyte retrieval increased the number
of in vivo matured oocytes and improved the in vitro oocyte
maturation rate as well as the clinical outcome in PCOS
patients undergoing IVM treatment cycles.
Materials and Methods
The initial IVM study was approved by the Research Institute of the
Hospital. The IVM treatment was explained to the patients, and
informed consent was obtained.
Patients
A total of 113 PCOS patients (120 cycles) were included in this
retrospective study. Between January 2006 and February 2007,
immature oocyte collection was performed after 35 h hCG priming
(Group 1; n ¼ 76), and between February 2007 and November
2007, oocyte retrieval was performed after 38 h hCG priming
(Group 2; n ¼ 44). There were no differences in the characteristics
of the IVM cycles between the two groups in terms of age, duration
of infertility, largest follicle diameter at retrieval, endometrial
thickness at retrieval or distribution of various follicle diameters on
hCG priming day (Table I). A 10 000 IU dose of hCG was admini-
strated in both groups. Women with amenorrhea received vaginally
300 mg of progesterone (Prometrium; Schering, Pointe-Claire,
Que ´bec, Canada) once daily for 10 days to induce withdrawal
bleeding. A baseline ultrasound scan was obtained for all women
between Days 2 and 4 of menstrual bleeding to ensure that no
ovarian cysts were present and to assess the antral follicle count
(AFC) (Tan et al., 2002). Transvaginal ultrasound scans were
repeated on Day 8 of the cycle or on the day of hCG administration.
Oocyte collection
Oocyte retrieval was performed between Days 10 and 16 of the men-
strual cycle based on the length of the patient’s cycle. A 10 000 IU
dose of hCG was administered when endometrial thickness reached
at least 6 mm. The number and measurement of follicles diameters
was calculated on the day of hCG administration. The largest follicle
and endometrial thickness were measured by ultrasound scan just
before oocyte collection. The size of the largest follicle was calculated
as a mean of two measurements in a two-dimensional plane. Transva-
ginal ultrasound-guided collection of oocytes was performed using a
19-gauge aspiration needle (K-OPS-7035-RWH-ET, Cook, Australia)
with a reduced aspiration pressure of 7.5 kPa. The aspirates were
collected in tubes with prewarmed heparinized saline. Collection
started with the largest follicle and oocyte maturity was assessed.
Subsequent collection of oocytes without follicle size measurement
was performed according to accessibility of the follicles after which
the maturity level of the oocyte was identiﬁed. To avoid the possibility
of missing oocytes with a small amount of CC, the remaining
follicular aspirates were ﬁltered using 70 mm mesh in hole size
(Falcon, Becton–Dickinson & Company, NJ, USA), washed three
timeswith oocyte washmedium(Cooper Surgical, CT, USA) thatcon-
tained HEPES buffer supplemented with recombinant human serum
albumin, and the oocytes isolated under a stereomicroscope.
In vitro maturation
The oocytes collected were assessed for nuclear maturity under the
dissecting microscope with high magniﬁcation ( 80) using the
sliding method (Chian et al., 2000; Son et al., 2006). If no germinal
vesicle (GV) was observed in the oocyte cytoplasm, the cumulus
masses were removed with hyaluronidase and mechanical pipetting,
and reassessment of maturity was performed. Oocytes that were
mature on the collection day (Day 0: 0–6 h) were inseminated on
the same day, whereas the immature oocytes (GV- or GV breakdown
(GVBD)-stage) were cultured in IVM medium (Cooper Surgical,
CT, USA) supplemented with 75 mIU/ml FSH and LH. Following
culture on Day 1 (24–30 h), the oocytes were denuded of CCs with
hyaluronidase and mechanical pipetting. After examination, immature
oocytes remaining at GV- or GVBD-stage were further cultured in
the same medium and the meiotic status was re-examined on Day 2
(48–52 h culture).
IVF, embryo development and transfer
Matured oocytes were inseminated by intracytoplasmic sperm injec-
tion (ICSI) using the partner’s spermatozoa. ICSI was performed at
least 1 h after observing ﬁrst polar body (PB) extrusion as suggested
by Hyun et al. (2007). Fertilization was assessed 17–19 h after
Table I. Characterization of hCG-primed IVM cycles in Groups 1 and 2.
Variables Group 1 (hCG þ 35 h) Group 2 (hCG þ 38 h) P value
No. of cycles (age, mean+SD) 76 (32.6+3.4) 44 (33.1+3.9) NS
Duration of infertility (years+SD) 3.8+0.4 3.7+0.3 NS
Endometrial thickness at collection (mm, mean+SD) 8.6+1.8 8.7+1.6 NS
Diameter of largest follicle at collection (mm, mean+SD) 11.6+4.0 11.6+3.0 NS
No. of follicles on the day of hCG priming
 6 mm (mean+SD) 25.1+11.2 23.7+9.6 NS
7–9 mm (mean+SD) 9.5+4.5 10.4+6.3 NS
 10 mm (mean+SD) 2.1+1.8 1.9+1.7 NS
Group 1: IVM cycles where oocytes were collected 35 h after hCG; Group 2: IVM cycles where oocytes were collected 38 h after hCG.
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2011insemination for the appearance of two distinct pronuclei and two
polar bodies. The zygotes were cultured in Embryo Maintenance
Medium (Cooper Surgical, CT, USA). Embryonic development was
assessed on Day 2 (41–43 h) and on Day 3 (65–67 h) after insemina-
tion according to the regularity of blastomeres, the percentage and
pattern of anucleate fragments, and all dysmorphic characteristics of
the embryos. For this study, we deﬁned embryos as good quality if
they had at least three-cells on Day 2 and six-cells on Day 3, contained
,20% anucleate fragments and exhibited no apparent morphological
abnormalities. Embryos showing blastomere multi-nucleation, poor
cell adhesion, uneven cell division and cytoplasmic abnormalities
were deﬁned as low quality.The best quality embryos were transferred
on Day 2 or 3 after ICSI.
Endometrium preparation
For endometrial preparation, patients received estradiol (E2) valerate
(Estrace; Roberts Pharmaceutical, Mississauga, Canada), starting
on the day of oocyte retrieval. If the endometrial thickness was
6–8 mm, an 8–10 mg dose was given, and if it was  8 mm, a 6 mg
dose was administered, all in divided doses. Luteal support was pro-
vided by administering 50 mg of progesterone daily intra-muscularly
starting on the day of ICSI and continued, along with E2 valerate, until
12 weeks of gestation, if the pregnancy test was positive.
Statistical analysis
Statistical analyses were performed using the x
2, Fisher’s exact or
t-test as appropriate. All P-values quoted are two-sided, and values
,0.05 indicate statistical signiﬁcance. Analyses were performed
using the SPSS statistical package (SPSS, Inc., Chicago).
Results
Fig. 1 shows the cumulus oocytes complex (COC) retrieved
from experimental groups as reported previously (Son et al.,
2006). Oocytes classiﬁed as having dispersed, compacted or
sparse CC appearances were collected. Fig. 2 shows the per-
centage of oocytes classiﬁed according to the appearance of
their cumulus at the time of oocyte retrieval in the two
groups. This ﬁgure shows that a higher number of oocytes
with dispersed CCs appeared in Group 2 (64.3%) compared
with that in Group 1 (37.5%) (P , 0.01).
Table II summarizes the embryological aspects and clinical
outcome in the hCG-primed IVM cycles of Groups 1 and 2. On
the day of oocyte retrieval, the number of in vivo matured
oocytes collected was signiﬁcantly higher (P , 0.01) in
Group 2 (13.6%, 114/840) than in Group 1 (7.3%, 96/1312).
All the in vivo matured oocytes collected in both groups
showed dispersed CCs. Fig. 3 shows the mean percentage of
oocytes at different stages of maturity on Days 0, 1 and 2 for
both groups. In both groups, all the oocytes that were still at
the GVBD-stage following 6 h culture on the day of retrieval
became mature by Day 1, together with a high proportion
of GV-stage oocytes. In contrast, in both groups, most of
the oocytes that mature by Day 2 were derived from oocytes
that were at the GVBD-stage on Day 1 (Fig. 3). The IVM
rate after Day 1 culture was signiﬁcantly higher (P , 0.01)
in Group 2 (46.3%) than in Group 1 (36.0%) (Fig. 4).
The IVM rate up to Day 2 was also signiﬁcantly higher
(P , 0.05) in Group 2 (68.2%) compared with that in Group
1 (62.3%) (Fig. 4).
Table III details the rates of maturation, fertilization, cleavage
and embryo development according to maturation time in the
two groups. The good quality embryo rate, deﬁned as the
number of good quality embryos divided by the number of
normal fertilized oocytes, was signiﬁcantly higher in the
embryos derived from the in vivo matured oocytes (Group 1 ¼
64.9%, Group 2 ¼ 62.4%) than from oocytes matured in vitro
on Day 1 (Group 1 ¼ 46.2%, Group 2 ¼ 42.9%) in both
groups (P , 0.01) (Table III). In both groups, the rates of ferti-
lization, cleavage and good quality embryos in oocytes matured
in vitro on Day 2 were signiﬁcantly lower than those in oocytes
matured in vitro on Day 1, as well as in vivo matured oocytes in
the both groups (P , 0.01). However, there was no signiﬁcant
difference in the fertilization and embryo developmental
competence in relation to the hCG priming time.
Although fertilization, cleavage and good quality embryo rates
were comparable between the two groups, the mean number of all
embryos available for transfer was signiﬁcantly higher in Group 2
compared with that in Group 1 (9.4+5.9 versus 7.4+5.7
embryos) (P , 0.01) (Table II). Of the 280 embryos transferred
in Group 1, 53 (18.9%), 178 (63.6%) and 49 (17.5%) were
derived from oocytes matured in vivo, and those in vitro
matured on Day 1 and Day 2, respectively. In Group 2, 34.4
(55/160), 63.1 (101/160) and 2.5% (4/160) of embryos trans-
ferred were derived from oocytes matured in vivo, and those in
vitro matured on Days 1 and 2, respectively. Therefore, more
embryos produced from in vivo matured oocytes were transferred
in Group 2 than in Group 1. The clinical pregnancy rate in Group
2 (40.9%) was higher than that in Group 1 (25%), but this was not
statistically signiﬁcant (P ¼ 0.1). The implantation rate in Group
2 (15.6%) was higher than that of Group 1 (9.6%), although the
difference did not reach statistical signiﬁcance (P ¼ 0.07).
Table IV details a comparison of clinical pregnancies
following transfer of the embryos derived from oocytes with
Figure 1: COC morphology of oocytes obtained in hCG-primed IVM cycles.
(a) A GV stage oocyte with dispersed CCs (b) a GV stage oocyte with compacted CCs (c) a GV stage oocyte with sparse CCs. Original magni-
ﬁcation ( 400). GV, germinal vesicle.
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2012different maturation times in hCG-primed IVM cycles. In both
groups, we observed higher clinical pregnancy rates in cycles
where embryos had been derived from in vivo matured
oocytes than in those where embryos had been derived from
in vitro matured oocytes.
Discussion
This study demonstrates that in programmed IVM cycles an
extension of the interval between hCG administration and
oocyte collection from 35 to 38 h results in a higher number
of in vivo and in vitro matured oocytes.
Although there have been conﬂicting reports on the clinical
outcome of FSH- or hCG priming before IVM (Mikkelsen
et al., 1999; So ¨derstro ¨m-Anttila et al., 2005), the advantages
of hCG-primed IVM cycles compared with that of non- or
FSH-primed IVM cycles have been reported (Son et al.,
2006, 2008). Technically, the CC expansion (dispersal) of the
oocytes caused by a high dosage of hCG (10 000 IU) facilitates
detachment and expulsion of the COC mass from the follicle
during the aspiration and thus makes oocyte collection easier
in hCG-primed IVM cycles than in non- or FSH-primed IVM
cycles (Son et al., 2006). Thus, oocytes with a dispersed CC
appearance can be obtained at the time of oocytes retrieval
only in hCG-primed IVM cycles (Yang et al., 2005; Son
et al., 2006). Those oocytes having dispersed CC are easy to
identify under a stereomicroscope without any ﬁltration
method, similar to the standard IVF technique (Son et al.,
2008). Regarding the embryological aspects, those immature
and in vivo matured oocytes with dispersed CC collected in
hCG-primed IVM cycles have shown good embryo develop-
mental competence (Son et al., 2002, 2006, 2008; Yang
Figure 2: Incidence of oocytes with CC appearances of either dis-
persed (B), compacted ( ), or sparse (A).
Group 1: IVM cycles where oocytes were collected 35 h after hCG.
Group 2: IVM cycles where oocytes were collected 38 h after hCG.
(a versus b) P , 0.01.
Table II. Maturation, fertilization, development and pregnancy rates in Groups 1 and 2.
Variables Group 1 (hCG þ 35 h) Group 2 (hCG þ 38 h) P value
No. of cycles 76 44
No. of cycles with in vivo matured oocytes (%) 38 (50) 36 (81.8) P , 0.01
No. of oocytes collected (mean+SD) 1312 (17.3+9.0) 840 (19.1+ 9.5) NS
No. of oocytes matured on collection day (%) 96 (7.3) 114 (13.6) P , 0.01
Mean+SD (range) 1.3+2.1 (0–12) 2.6+2.8 (0–12) P , 0.01
No. of oocytes cultured in vitro 1216 726
No. of oocytes matured in vitro on Day 1(%) 438 (36.0) 336 (46.3) P , 0.01
No. of oocytes matured in vitro on Day 2(%) 320 (26.3) 159 (21.9) NS
No. of MII oocytes matured in vitro (%) 758 (62.3) 495 (68.2) P , 0.05
No. of total MII oocytes (%) 854 (65.1) 609 (72.5) P , 0.01
No. of normal fertilized oocytes (%) 623 (73.0) 447 (73.4) NS
No. of embryos cleaved (%) 560 (89.9) 413 (92.4) NS
Mean no. of embryos available for ET 7.4+5.7 9.4+5.9 P , 0.01
No. of transferred embryos (mean+SD) 280 (3.7+1.0) 160 (3.6+0.9) NS
No. of clinical pregnancies (%) 19 (25.0) 18 (40.9) P ¼ 0.1
No. of implantations (%) 27 (9.6) 25 (15.6) P ¼ 0.07
Group 1: IVM cycles where oocytes were collected 35 h after 10 000IU hCG; Group 2: IVM cycles where oocytes were collected 38 h after 10 000 IU hCG.
NS, non signiﬁcant.
Figure 3: Mean percentage of oocytes (mean % +SD) at Metaphase
II- (A), GVBD- ( ), or GV (B)-stage on collection day (Day 0), on
Day 1 and on Day 2 culture in Group 1 (hCG þ 35 h) and Group 2
(hCG þ 38 h).
Day 0: 0–6 h after culture, 1: 24–30 h after culture, Day 2: 48–52 h
after culture. GVBD¼germinal vesicle breakdown, GV¼germinal
vesicle. (a versus b) P , 0.01, (c versus d) P , 0.01.
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2013et al., 2005). Therefore, the dispersed CC pattern at the time of
aspiration in hCG-primed IVM cycles can be predictive
of higher maturation rates and of embryonic developmental
competence. In this study, 38 h of hCG priming produced a
signiﬁcantly higher number of oocytes with dispersed CC
than did 35 h of priming.
Administration of hCG is normally used to substitute the LH
surge and triggers the ﬁnal oocyte maturation before retrieval.
In COH cycles, several reports have been published on the
effect of extending the time between oocyte collection and
hCG injection on oocyte maturation and embryonic develop-
mental competence. Although Bjercke et al. (2000) could not
ﬁnd any difference between 34 and 38 h of oocyte exposure
to hCG, other studies suggested that prolonging the interval
to oocyte retrieval increased the rate of in vivo oocyte matu-
ration and the number of high quality cleaving embryos in
COH cycles (Gudmundsson et al., 1990; De Vits et al., 1994;
Raziel et al., 2006). Recently, a similar clinical approach was
adopted in another IVF clinic and the positive effects were
conﬁrmed after performing COH in patients who had a high
percentage of immature oocytes in previous cycles (Raziel
et al., 2006). The investigators assumed that the longest
interval would yield oocytes in which all cellular and nuclear
maturation processes would have been completed and therefore
the mature oocytes collected would be more likely to develop
into 2PN zygotes and normally cleaving embryos.
For hCG-primed IVM programs, we considered two
methods to increase the number of oocytes with dispersed
CC: a time-dependent and dose-dependent response on hCG
priming. The effect of a dose-effective response 36 h after
hCG priming has already been studied on embryological
aspects in IVM cycles (Gulekli et al., 2004). In that study,
the authors compared the IVM, fertilization and embryo
development rates between oocytes collected after 10 000
and 20 000 IU hCG priming in patients who underwent IVM
cycles. Although the fertilization rate was signiﬁcantly lower
in the group that had been stimulated with 20 000 IU hCG
compared with that in the group stimulated with 10 000 IU,
the maturation and cleavage rates were similar between the
two groups. Based on the ﬁnding of that study, it seems that
there is no dose-dependent effect of the hCG on in vivo
or/and in vitro oocyte maturation in IVM cycles. However,
there was no mention about the difference in CC appearance
and in vivo matured oocytes in the report.
Therefore, this study was conducted to evaluate a time-
dependent effect on hCG-primed IVM cycles. In comparison
with COH cycles, there is no risk of ovulation by delaying
Figure 4: Time course of oocyte maturation during culture in vitro of
human immature oocytes in cycles where oocytes were collected
either 35 h after hCG (Group 1, A) or 38 h after hCG (Group 2, B).
Day 0: 0–6 h after culture, Day 1: 24–30 h after culture, Day 2:
48-52 h after culture. *P , 0.01 or **P , 0.05. Signiﬁcant difference
between two groups at the time point.
Table III. Details in embryology of hCG-primed IVM cycles in Groups 1 and 2.
Groups Group 1 (hCG þ 35 h) Group 2 (hCG þ 38 h)
Day of maturity and ICSI Day 0 Day 1 Day 2 Day 0 Day 1 Day 2
No. of MII oocytes 96 438 320 114 336 159
No. of fertilized oocytes (%) 74 (77.1)
a 344 (78.5)
a 205 (64.1)
b 85 (74.6)
a 268 (79.8)
a 94 (59.1)
b
No. of cleaved embryos (%) 72 (97.3)
a 332 (96.5)
a 156 (76.1)
b 84 (98.8)
a 256 (95.5)
a 73 (77.7)
b
No. of good quality embryos (%*) 48 (64.9)
a 159 (46.2)
b 40 (19.5)
c 53 (62.4)
a 115 (42.9)
b 15 (16.0)
c
Group 1: IVM cycles where oocytes were collected 35 h after hCG; Group 2: IVM cycles where oocytes were collected 38 h after hCG.
*The number of good quality embryos divided by number of fertilized oocytes.
a versus bP , 0.05.
a,b,cDifferent letters superscripts denote signiﬁcant differences (P , 0.01) among values within row in each hCG timing group.
Table IV. Details in comparison of clinical pregnancies following transfer of
the embryos derived from oocytes matured according to maturation day in
hCG-primed IVM cycles.
ET of embryos derived
from oocytes matured on
Group 1 Group 2
No. of CP/no. of
ET cycles (%)
No. of CP/no. of
ET cycles (%)
Day 0 3/6 (50.0) 3/5 (60.0)
Day 0þDay 1 6/18 (33.3) 11/25 (44.0)
Day 0þDay 1þDay 2 2/6 (33.3) 0/2 (0.0)
Day 1 6/22 (27.3) 4/11 (36.4)
Day 1þDay 2 1/19 (5.3) 0/1 (0.0)
Day 2 1/5 (20.0) —
Total clinical pregnancy
rate (%)
19/76 (25.0) 18/44 (40.9)
CP, clinical pregnancies; ET, embryo transfer. Group 1: IVM cycles where
oocytes were collected 35 h after hCG; Group 2: IVM cycles where oocytes
were collected 38 h after hCG.
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2014oocyte collection after hCG stimulation in patients undergoing
IVM cycles since the largest follicle size at the time of hCG
administration is 8–12 mm. In the present study, a positive
correlation was observed between delayed collection time
after hCG priming and the number of oocytes with dispersed
CC generated in hCG-primed IVM cycles (Fig. 2). This
ﬁnding is in agreement with Gudmundsson et al. (1990), who
described a signiﬁcantly higher number of oocytes with fully
expanded CC after delayed oocyte retrieval (39 h) in COH
cycles. Therefore, we believe that prolonging the interval
between hCG administration and oocyte collection in IVM
cycles is a valuable treatment to collect more oocytes stimu-
lated in an in vivo environment for PCOS patients.
In the present study, we assessed whether the presence of a
highnumber ofoocytes with dispersed CC at the time of collec-
tion in hCG-primed IVM cycles was positively correlated to in
vivo and in vitro oocyte maturation. The rate of in vivo matured
oocytes in Group 2 (13.6%, mean ¼ 2.6) was signiﬁcantly
higher compared with that in Group 1 (7.3%, mean ¼ 1.3)
(Table II). Therefore, there was a higher chance of retrieving
in vivo matured oocytes at the time of retrieval in Group 2
(hCG þ 38 h) compared with that in Group 1 (hCG þ 35 h),
even when the largest follicle size was similar between both
groups (Table I). Actually, the smallest follicle size from
which an in vivo matured oocyte was collected was 8 mm in
Group 1, whereas in Group 2 it was as small as 6 mm. This
is in agreement with Bokal et al. (2005), who found a signiﬁ-
cantly higher number of MII oocytes in HCG þ 38 h group
than in hCG þ 34 h in COH cycles. When we analyzed the
embryological aspects of both groups in detail, we conﬁrmed
that oocytes matured in vivo possessed a signiﬁcantly higher
developmental potential than those oocytes matured in vitro
(Table III) for both groups, resulting in higher clinical preg-
nancy rates in cycles that had transferred embryos derived
from in vivo matured oocytes (Table IV).
Although there was no difference in the mean percentage of
GVBD-stage oocytes on collection day between the two groups
(Fig. 3), the IVM rate after Day 1 of culture in Group 2 was sig-
niﬁcantly higher (46.3%) than that of Group 1 (36%) (Fig. 4),
suggesting that the follicles in Group 2 can produce GV-stage
oocytes that possess the potential to mature faster in vitro by
extending hCG stimulation for three more hours. As reported
previously (Barnes et al., 1996; Son et al., 2005), those
oocytes that ﬁrst reach MII stage in IVM cycles are usually
the most competent to develop into blastocysts. The in vitro
matured oocytes after Day 1 produced better quality embryos
than those that had matured late (Day 2) in both Groups 1
and 2 (Table III). Therefore, this study demonstrated that an
increased number of oocytes with dispersed CC following
prolonged hCG stimulation was positively correlated with the
number of in vivo and in vitro matured oocytes. However,
there was no signiﬁcant difference in fertilization and
embryonic developmental competence between oocytes
matured on the same day in Groups 1 and 2 (Table III).
As shown in Table IV, in both groups, the clinical pregnancy
rate in cycles where embryos were derived from in vivo or/and
Day 1 in vitro matured oocytes was higher than that where
embryos were derived from late matured oocytes (Day 2).
Most of the cycles in Group 2 had transferred embryos
derived from oocytes matured in vivo and/or in vitro on Day
1 compared with cycles in Group 1 (Table IV). Therefore,
the trend of better pregnancy outcome in the hCG þ 38 h
IVM cycles is attributed to the increase in the quantity of
embryos available to select for transfer, since the percentages
of oocytes matured in vivo and those matured faster in vitro
were improved with prolonged hCG exposure. In fact, the
mean number of all embryos available in Group 2 was
signiﬁcantly higher than in Group 1 (9.4 and 7.4 embryos,
respectively) (Table II).
The present study indicates that a larger cohort of oocytes
matured in vivo and in vitro can be recruited by permitting
hCG action for three more hours. In COH cycles, Bokal
et al. (2005) suggested that the longer exposure to hCG
increased follicular vascularization and thus oocyte quality
due to a high concentration of vascular endothelial growth
factor (VEGF). Therefore, it is tempting to speculate that in
IVM cycles the hCG action for three more hours would
allow follicles to produce more VEGF, increasing oocyte matu-
ration. However, in IVM cycles, it is hard to conﬁrm the effect
of VEGF since it is difﬁcult to get follicular ﬂuid from each fol-
licle due to its small size. Another possibilitycould be that even
though there is no direct evidence on the appearance of
LH-receptors (LH-R) in folliculogenesis, it is possible that
some small follicles with insufﬁcient LH-R might have
responded following exposure for a longer time to hCG (35
versus 38 h), resulting in an increased number of oocytes
with dispersed CC and a reduced number of oocytes with com-
pacted or sparse CC. Interestingly, LH-R expression has been
conﬁrmed in dispersed CCs of oocytes generated from
hCG-primed IVM cycles (Yang et al., 2005). Willis et al.
(1998) have reported that unstimulated granulosa cells
retrieved from anovulatory women with polycystic ovaries
responded to LH in small follicles of 4 mm. In spite of the
exposure to large doses of hCG (10 000 IU) for three more
hours, the presence of compact CCs around oocytes could be
due to LH-R which is still insufﬁcient to induce the CC
response in vivo. Meanwhile, the oocytes with sparse CCs
might be mixed with oocytes with CCs removed mostly by
pressure on ovum aspiration and that were entering the degen-
erative process. A well-deﬁned study is needed to ascertain
these possibilities.
In conclusion, our results suggest that the extension of the
interval between hCG priming and oocyte retrieval to 38 h in
programmed IVM cycles promotes in vivo and in vitro
oocyte maturation. The prolonged exposure to hCG seems to
be a promising alternative protocol to be used in IVM cycles.
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